KFDA to give disadvantages when not presenting bio-equivalent test items.

The KFDA intends to give disadvantages to the drug company who declines to carry out the bio-equivalent test for the items the company already applied for the test.

When the drug of high strength with the same dosage form manufactured by the same company completed its bio-equivalent test, the drug of its lower strength shall exempt the same test if the same inactive substances with the drug ...